- Home
- SWK vs EXEL Comparison
SWK vs EXEL Comparison
Compare SWK & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWK
- EXEL
- Stock Information
- Founded
- SWK 1843
- EXEL 1994
- Country
- SWK United States
- EXEL United States
- Employees
- SWK N/A
- EXEL N/A
- Industry
- SWK Industrial Machinery/Components
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SWK Consumer Discretionary
- EXEL Health Care
- Exchange
- SWK Nasdaq
- EXEL Nasdaq
- Market Cap
- SWK 10.5B
- EXEL 10.4B
- IPO Year
- SWK N/A
- EXEL 2000
- Fundamental
- Price
- SWK $67.90
- EXEL $40.99
- Analyst Decision
- SWK Buy
- EXEL Buy
- Analyst Count
- SWK 9
- EXEL 24
- Target Price
- SWK $92.25
- EXEL $44.73
- AVG Volume (30 Days)
- SWK 2.0M
- EXEL 3.2M
- Earning Date
- SWK 11-04-2025
- EXEL 11-04-2025
- Dividend Yield
- SWK 4.89%
- EXEL N/A
- EPS Growth
- SWK N/A
- EXEL 53.55
- EPS
- SWK 2.90
- EXEL 2.38
- Revenue
- SWK $15,166,300,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- SWK $0.46
- EXEL $9.14
- Revenue Next Year
- SWK $3.65
- EXEL $12.51
- P/E Ratio
- SWK $23.45
- EXEL $17.42
- Revenue Growth
- SWK N/A
- EXEL 9.93
- 52 Week Low
- SWK $53.91
- EXEL $31.90
- 52 Week High
- SWK $93.63
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- SWK 44.48
- EXEL 59.59
- Support Level
- SWK $66.50
- EXEL $36.00
- Resistance Level
- SWK $71.80
- EXEL $41.55
- Average True Range (ATR)
- SWK 2.48
- EXEL 1.40
- MACD
- SWK 0.03
- EXEL 0.32
- Stochastic Oscillator
- SWK 32.18
- EXEL 91.61
About SWK Stanley Black & Decker Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates in two reportable segments namely Tools and Outdoor and Industrial. It generates maximum revenue from the Tools and Outdoor segment. The Tools and Outdoor segment is comprised of the Power Tools Group (PTG), Hand Tools, Accessories and Storage (HTAS), and Outdoor Power Equipment (Outdoor) businesses. Geographically, the company generates revenue from the United States, Canada, Other Americas, Europe, and Asia. It derives a majority of its revenue from the United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.